clopidogrel + omeprazole
Phase 3- Indications
- Cardiovascular disease, Gastrointestinal bleeding prevention
Company intelligence / Profile preview
Cogentus Pharmaceuticals
Menlo Park, California, United Statesbiospace.com ↗
- Ownership
- Private
- Development stage
- Phase 3
01
Overview
Lead product CGT‑2168, a fixed-dose combination of clopidogrel and omeprazole, advanced to Phase 3 trials to reduce GI bleeding risk in patients requiring antiplatelet therapy. Earlier studies showed pharmacodynamic equivalence to Plavix without interference from omeprazole. No recent clinical results available.
- Therapeutic areas
- GastroenterologyCardiovascular
- Modalities
- Small molecules (combination products)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Cogentus Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cogentus Pharmaceuticals.